Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.

Cancer cell - 14 Jul 2025

Benton Alexander, Liu Jiageng, Poussin Mathilde A, Lang Goldgewicht Andrea, Udawela Madhara, Bear Adham S, Wellhausen Nils, Carreno Beatriz M, Smith Pete M, Beasley Matthew D, Kiefel Ben R, Powell Daniel J

Abstract excerpt

Despite the success of chimeric antigen receptor (CAR)-T cell therapies in hematological malignancies, clinical success against solid tumors is limited due to low therapeutic efficacy or dose-limiting toxicity. Developing therapies that trigger potent, yet manageable, immune responses capable of eliminating highly heterogeneous and immunosuppressive tumor cell populations remains a key challenge. Here, we harness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy, Adoptive
Share to Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Antigen, T-Cell

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40480232
DOI: 10.1016/j.ccell.2025.05.006
PMCID: PMC12263316

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.PMID 40480232Read ↗

Functional avidity enhancement of a T-cell receptor targeting the KRASG12D cancer neoantigen.Semantic proximity Read ↗

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Semantic proximity Read ↗

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen SelectivitySemantic proximity Read ↗

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read ↗

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read ↗

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read ↗

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.Semantic proximity Read ↗

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read ↗

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read ↗

Overcoming immune evasion from post-translational modification of a mutant KRAS epitope to achieve TCR-T cell-mediated antitumor activitySemantic proximity Read ↗

Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors.Semantic proximity Read ↗

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.